Nov 30, 2021 / NTS GMT
David Newman - Desjardins Group - Analyst
Good afternoon. Welcome back. My name is David Newman, Desjardins diversified industries analyst covering the healthcare tech industry. I welcome to our next session with Think Research, joined by Sachin Aggarwal, CEO, and Jae Cornelssen, CFO. We have a buy on the stock and a $4 target price.
Think is driving solutions across the healthcare backbone, spanning knowledge, research, connectivity, and services. Its tools are being used to organize medical knowledge and patient data, reduce healthcare costs, and improve, most importantly, healthcare outcomes. It's a SaaS-driven, highly predictable model, focus on B2B and B2G. It's been a -- they've been busy on the acquisition front with the recent BioPharma and Pharmapod acquisitions.
Sachin and Jae, welcome, and thank you for joining this for the first time this year. So, welcome, and over to you for some opening comments.
Sachin Aggarwal - Think Research Corporation - CEO
Yeah. And thanks, David, for having us. This is always a real pleasure to be working
Think Research Corporation at Desjardins Digital Healthcare Conference (Virtual) Transcript
Nov 30, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers